{"nctId":"NCT00993824","briefTitle":"Glycemic Effect of Colesevelam HCl (Welchol) in Patients With Type 2 Diabetes","startDateStruct":{"date":"2009-09"},"conditions":["Type 2 Diabetes"],"count":21,"armGroups":[{"label":"Welchol then Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: colesevelam HCl","Drug: placebo"]},{"label":"Placebo then Welchol","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: colesevelam HCl","Drug: placebo"]}],"interventions":[{"name":"colesevelam HCl","otherNames":["Welchol"]},{"name":"placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Male or female subjects ≥18 and ≤75 years of age\n* Clinical diagnosis of type 2 diabetes\n* Currently treated with metformin, a sulfonylurea, or combination metformin/sulfonylurea; stable dose for ≥3 months\n* HbA1c of 7.0-9.0% inclusive\n* If taking lipid lowering medications, stable dose for \\>30 days\n\nExclusion Criteria:\n\n* Taken oral or injected prednisone or cortisone medications in the previous 30 days. (Topical or inhaled steroids will not be considered excluded medications.)\n* Current use of insulin or TZD's, or incretins\n* LDL \\<70 mg/dL\n* Serum triglycerides \\>500 mg/dL\n* History of hypertriglyceridemia-induced pancreatitis\n* History of gastrointestinal disorder such as dysphagia, swallowing disorder, intestinal motility disorder or prior bowel obstruction\n* History or presence of any severe medical or psychological condition or chronic conditions/infections that in the opinion of the Investigator would compromise the subject's safety or successful participation in the study\n* Unable to follow the study protocol\n* Unable to speak, read and write in English\n* Pregnant, planning to become pregnant, breast feeding","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"75 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Total Norm AUC Average by Group (Normalized)","description":"Double Blinded CGM used for 2 week periods at the start of treatment 1, end of treatment 1, start of treatment 2, and end of treatment 2.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"150.8","spread":"10.8"},{"groupId":"OG001","value":"175.9","spread":"29.2"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"149.9","spread":"17.2"},{"groupId":"OG001","value":"175.1","spread":"27.4"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"163.2","spread":"23.5"},{"groupId":"OG001","value":"159.4","spread":"23.9"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"177.9","spread":"33.2"},{"groupId":"OG001","value":"159.4","spread":"25.3"}]}]}]},{"type":"PRIMARY","title":"Sleep Norm AUC Average by Group (Normalized)","description":"Overnight glucose captured by CGM.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"147.4","spread":"16.6"},{"groupId":"OG001","value":"161.9","spread":"25.7"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"148.0","spread":"24.0"},{"groupId":"OG001","value":"160.2","spread":"27.9"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"158.8","spread":"31.8"},{"groupId":"OG001","value":"147.9","spread":"24.4"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"172.0","spread":"32.5"},{"groupId":"OG001","value":"143.6","spread":"18.6"}]}]}]},{"type":"PRIMARY","title":"Wake Norm AUC Average by Group (Normalized)","description":"Wake glucose captured by continuous glucose monitoring (CGM).","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"153.3","spread":"11.7"},{"groupId":"OG001","value":"180.9","spread":"32.2"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"151.2","spread":"16.0"},{"groupId":"OG001","value":"180.6","spread":"29.6"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"165.2","spread":"21.2"},{"groupId":"OG001","value":"163.8","spread":"25.6"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"180.9","spread":"34.2"},{"groupId":"OG001","value":"165.2","spread":"30.5"}]}]}]},{"type":"PRIMARY","title":"Hypoglycemia Percentage of Time <70 mg/dL Average by Group","description":"Ambulatory glucose profile (AGP) reports were examined for the changes in the incidence of hypoglycemia (CGM\\<70 mg/dL)","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.2","spread":"1.3"},{"groupId":"OG001","value":"0.3","spread":"0.6"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.8","spread":"1.1"},{"groupId":"OG001","value":"0.4","spread":"0.6"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.8","spread":"1.2"},{"groupId":"OG001","value":"0.7","spread":"1.0"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.6","spread":"1.2"},{"groupId":"OG001","value":"0.6","spread":"1.1"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":21},"commonTop":[]}}}